UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
May 6, 2014
| TRANSGENOMIC, INC. | ||
| (Exact name of registrant as specified in its charter) | ||
| Delaware | 000-30975 | |
| (State or other jurisdiction of incorporation) | (Commission File Number) | |
| 91-1789357 | ||
| (IRS Employer Identification Number) | ||
| 12325 Emmet Street Omaha, NE |
68164 | |
| (Address of principal executive offices) | (Zip Code) | |
| (402) 452-5400 | ||
| (Registrant’s telephone number, including area code) | ||
| Not applicable | ||
| (Former name or former address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e(c))
Item 8.01. Other Events.
On May 6, 2014, Transgenomic, Inc., a Delaware corporation (“Transgenomic”), issued a press release announcing that The Nasdaq Stock Market LLC approved Transgenomic’s application to have its common stock, par value $0.01 per share (“Common Stock”), listed on The Nasdaq Capital Market. The Common Stock is expected to begin trading on The Nasdaq Capital Market on Friday, May 9, 2014 under the symbol “TBIO.” The Common Stock will continue to trade on the OTCQB under the symbol “TBIO” until the market closes on Thursday, May 8, 2014. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press Release dated May 6, 2014, Announcing the Approval of the Listing of its Common Stock on The Nasdaq Capital Market |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TRANSGENOMIC, INC. | |||
| May 6, 2014 | By | /s/ Mark P. Colonnese | |
|
Mark P. Colonnese
| ||
Exhibit 99.1
Transgenomic Announces Uplisting to the NASDAQ Capital Market
OMAHA, Neb. (May 6, 2014) -- Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic tests and clinical and research services, today announced that its shares of common stock have been approved for uplisting to the NASDAQ Capital Market. Effective Friday, May 9, 2014, the stock will trade on NASDAQ under the symbol TBIO.
“Uplisting to Nasdaq represents a key milestone for Transgenomic as we continue our transition into a leading player in the rapidly growing field of personalized medicine,” said Paul Kinnon, President and Chief Executive Officer of Transgenomic. “Uplisting to a national exchange was an important goal for the company. We believe that trading on the NASDAQ market will expand our visibility and provide us access to a broader investor base, helping us translate our strategic growth initiatives and renewed focus on implementation into increased shareholder value going forward.”
Transgenomic develops and commercializes diagnostic assays and testing kits with the goal of improving medical diagnoses and patient outcomes.
Transgenomic’s common shares will continue to trade on the OTC Bulletin Board under its existing ticker symbol "TBIO" until the market closes on Thursday, May 8, 2014.
About Transgenomic
Transgenomic, Inc. is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through advanced diagnostic technologies, such as its revolutionary ICE COLD-PCRTM and its unique genetic tests through our Patient Testing business. The company also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies, and sells equipment, reagents and other consumables for applications in molecular testing and cytogenetics. Transgenomic’s diagnostic technologies are designed to improve medical diagnoses and patient outcomes.
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Contact:
Investor Contact:
Argot Partners
David Pitts, 212-600-1902
david@argotpartners.com
Media Contact:
BLL Partners LLC
Barbara Lindheim, 212-584-2276
blindheim@bllbiopartners.com
Company Contact:
Transgenomic,
Inc.
Donna Christian, 402-452-5416
investorrelations@transgenomic.com